It is recommended that the dosages used should be at the lower end of the normal range (for controls of blood count see section 4.4).

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.To bookmark a medicine you must sign up and log in.To view the changes to a medicine you must sign up and log in. By continuing to browse the site you are agreeing to our policy on the use of cookies. Therefore, the risk of developing tumours is higher when the agent is used in connection with transplantation than with the other indications. • Seriously impaired hepatic or bone marrow function When handling this substance appropriate precautions must be taken. It can take weeks or months before therapeutic effect is seen.The medicinal product may be given over the long term unless the patient cannot tolerate the preparation.In cases, such as rheumatoid arthritis and certain haematological conditions, the treatment can be stopped after a certain period without problems.Withdrawal of azathioprine should always be a gradual process performed under close monitoring.Halving of the film-coated tablet should be avoided unless needed for gradual withdrawal (see sections 4.4 and 6.6).



For appropriate long-term dosing other medicinal products containing 25mg should be used, if necessary.The tablet should be taken with at least a glass of liquid (200 ml). Physicians should be attentive to symptoms of infection such as EBV and cytomegalovirus (CMV), as these are known triggers for MAS.Patients with inherited mutated NUDT15 gene are at increased risk for severe 6-mercaptopurine toxicity, such as early leukopenia and alopecia, from conventional doses of thiopurine therapy. Also in patients with hepatic impairment the metabolism of azathioprine is altered.

Significant leucopenia in 5.3% of RA patients.

2002 on prescription).

The maintenance dosage required may range from less than 1mg/kg body weight/day to 3mg/kg/body weight/day depending on the clinical condition being treated and the individual patient response including haematological tolerance.In patients with renal and/ or mild to moderate hepatic dysfunction, dosages should be given at the lower end of the normal range.



In rabbits, a dose of 5-15 mg/kg body weight daily on days 6-14 of pregnancy produced skeletal abnormalities, in mice and rats, doses of 1-2 mg/kg body weight daily on days 3-12 were lethal to embryos.In long-term carcinogenicity studies of azathioprine in mice and rats, an increased incidence of lymphosarcomas (mice) and epithelial tumours and carcinomas (rats) were observed at dosages that were up to 2-fold the human therapeutic dosage.Store in the original package in order to protect from light.There are no risks associated with handling tablets with intact coating. The increased risk appears to be related to the degree and duration of immunosuppression. Consequently they may be exposed to an increased myelotoxic effect.

The dosage is usually higher for this indication in connection with transplantation. • All tablets which reduce gastric acid (omeprazole, lansoprazole, ranitidine) • All thyroid drugs • All major and minor tranquilisers, which are taken regularly at home. When the therapeutic response is evident consideration should be given to reducing the maintenance dosage to the lowest level compatible with maintenance of the response.

However, the following mechanisms of action have been suggested:i.

Patients should be advised to inform their anaesthesiologist of their treatment with azathioprine prior to surgery.Coagulation should be closely monitored when anticoagulants of the coumarin type are given concomitantly with azathioprine (see section 4.5).Withdrawal of azathioprine can result in a severe worsening of the condition, e.g.

A single large dose of azathioprine is less likely to have a toxic effect than a chronic minor overdose (e.g. 2010 azasan-imuran-azathioprine-343191 Granulocytopenia, pancytopenia and aplastic anaemia, megaloblastic anaemia, erythro hypoplasia. The damage of deoxyribonucleic acid (DNA) through incorporation of purine thio-analogues.Azathioprine is well absorbed following oral administration. An ECG showed atrial fibrillation, and the patient reported that the symptoms were similar to those experienced previously.

Experimental data confirm that azathioprine reverses the neuromuscular blockade produced by d-tubocurarine, and show that azathioprine potentiates the neuromuscular blockade produced by succinylcholine (see section 4.4).If azathioprine is combined with other immunosuppressants, such as cyclosporin or tacrolimus, the greater risk of excessive immunosuppression must be taken into consideration.





Dose increases: Every 2 weeks until dose is stable for 6 weeks, then revert to previous schedule.

Contact the applicable plan

AST, aspartate transaminase; ALT, alanine aminotransferase; GFR, glomerular filtration rate.

and formulary information changes. The inhibition of many pathways in nucleic acid biosynthesis, hence preventing proliferation and activity of immunocompetent cells (B- and T-lymphocytes).iv. Individual plans may vary Colitis, diverticulitis.

In any case, close monitoring of blood counts is necessary.There are insufficient data to recommend the use of azathioprine for the treatment of juvenile chronic arthritis, systemic lupus erythematosus, dermatomyositis, and polyarteriitis nodosa.Concerning the other indications the given dose recommendations apply for children and adolescents as well as for adults.There is no specific information on how elderly patients tolerate azathioprine. Your list will be saved and can be edited at any time.The above information is provided for general Please see ... Lansoprazole (paediatrics) Formulary: First choice PPI in children >3.5kg (see omeprazole for children <3.5kg) Break tablet and disperse the portion in water BNFC dosing (lansoprazole) Leeds Cystic Fibrosis guidelines Paediatric Prescribing and Administration guide: lansoprazole (and omeprazole) …



When suggestions are available use up and down arrows to review and ENTER to select. … This website also contains material copyrighted by 3rd parties. Special care should therefore be taken during co-administration of aminosalicylate derivatives, including sulphasalazine, which are inhibitors of the TPMT enzyme.